ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Misoprostol: Drug information

Misoprostol: Drug information
(For additional information see "Misoprostol: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Patients who could become pregnant:

Misoprostol administration to women who are pregnant can cause birth defects, abortion, premature birth, or uterine rupture. Uterine rupture has been reported when misoprostol was administered in pregnant women to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery. Misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by NSAIDs.

Patients must be advised of the abortifacient property and warned not to give the drug to others.

Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period.

Brand Names: US
  • Cytotec
Pharmacologic Category
  • Prostaglandin
Dosing: Adult
Cervical ripening and labor induction

Cervical ripening and labor induction (off-label use):

Note: The safest and most effective regimen has not been established; additional studies are needed. Various routes of administration and doses have been evaluated (Ref). Intravaginal (Ref) and oral routes (Ref) are recommended based on currently available data. Buccal (Ref) and sublingual routes (Ref) have also been studied.

Intravaginal (off-label route): 25 mcg (one-fourth of 100 mcg tablet); may repeat at intervals no more frequent than every 3 to 6 hours; 50 mcg every 6 hours may be used in some cases but may be associated with an increased risk of adverse events (Ref). Additional regimens have been studied (Ref).

Oral: 25 mcg (one-fourth of 100 mcg tablet) every 2 hours (Ref) or 20 mcg every 2 hours (by dissolving the tablet to make an oral solution) (Ref); additional regimens have been studied (Ref). Low oral doses have a lower risk of cesarean delivery or failed vaginal delivery and less hyperstimulation compared to vaginal administration (Ref).

Early pregnancy loss

Early pregnancy loss (off-label use): Intravaginal (off-label route): Initial dose: 800 mcg in patients <13 weeks' gestation. May repeat with one dose if needed, ≥3 hours after the first dose and typically within 7 days if no response to the initial dose is observed. Consider using in combination with oral mifepristone when mifepristone is available (Ref). Alternately, misoprostol may be administered buccally or sublingually (Ref).

Incomplete abortion, treatment

Incomplete abortion, treatment (off-label use): Note: A systematic review suggests additional data may be needed to determine the most effective dose and route of administration. Most available data are for patients <13 weeks' gestation (Ref).

Oral: 600 mcg as a single dose in patients <14 weeks' gestation (Ref).

Sublingual (off-label route): 400 mcg as a single dose in patients <14 weeks' gestation (Ref). Dose may be repeated every 3 hours for patients ≥14 weeks' gestation. Caution should be used in patients with a prior uterine incision; clinical judgement is needed to determine number of doses. Consider the possibility of uterine rupture with advanced gestational age (Ref).

Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention

Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention: Oral: 200 mcg 4 times daily; if not tolerated, may decrease dose to 100 mcg 4 times daily.

Postpartum hemorrhage

Postpartum hemorrhage (off-label use):

Note: Misoprostol as adjunctive therapy with oxytocin has been used in high-risk patients; monotherapy is recommended in situations where oxytocin is not available (eg, resource-poor settings). The risk of adverse reactions may be associated with combination therapy, dose, and/or route of administration. Additional data may be necessary to further define the optimal dose and route of administration (Ref).

Prevention:

Buccal/sublingual (off-label route): 200 to 400 mcg as a single dose administered immediately after delivery (as adjunctive therapy with oxytocin) (Ref).

Oral: 400 to 600 mcg as a single dose administered immediately after delivery (Ref).

Treatment:

Oral: 600 to 1,000 mcg as a single dose (Ref); when used as adjunctive treatment, lower doses (200 to 400 mcg) may be sufficient (Ref).

Rectal (off-label route): 600 to 1,000 mcg as a single dose (Ref).

Sublingual (off-label route): 800 mcg as a single dose. Use caution if a prophylactic dose was already given, especially if adverse events were observed (Ref). Dosage ranges of 600 to 1,000 mcg as a single dose have been noted (Ref), however, lower doses (200 to 400 mcg) may be sufficient as adjunctive therapy (Ref).

Termination of intrauterine pregnancy, combination therapy

Termination of intrauterine pregnancy, combination therapy: Refer to Mifepristone monograph.

Termination of intrauterine pregnancy, monotherapy

Termination of intrauterine pregnancy, monotherapy (off-label use): Note: Monotherapy may be used when mifepristone is not available; however, misoprostol monotherapy is less effective (Ref). Vaginal administration should be avoided in patients with bleeding or signs of infection (Ref).

Patients <13 weeks' gestation: 800 mcg sublingually every 3 hours for 2 to 3 doses. Alternately, may be administered vaginally or buccally every 3 to 12 hours for 2 to 3 doses (Ref).

Patients 13 to 24 weeks' gestation: 400 mcg vaginally, sublingually, or buccally every 3 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion (Ref).

Patients 25 to 26 weeks’ gestation: 200 mcg vaginally, sublingually, or buccally every 4 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion (Ref).

Patients 27 to 28 weeks’ gestation: 200 mcg vaginally, sublingually, or buccally every 4 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion. Data is insufficient to recommend use in patients with a prior cesarean delivery or transmural uterine scar (Ref).

Patients >28 weeks’ gestation: 100 mcg vaginally, sublingually, or buccally every 6 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion. Data is insufficient to recommend use in patients with a prior cesarean delivery or transmural uterine scar (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Dose adjustment is not routinely needed; however, the dose may be reduced if the recommended dose is not tolerated. It is not known if misoprostol is removed by dialysis.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Nonsteroidal anti-inflammatory-induced gastric ulcers, prevention: Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%: Gastrointestinal: Abdominal pain, diarrhea (including severe diarrhea)

1% to 10%:

Gastrointestinal: Constipation, dyspepsia, flatulence, nausea, vomiting

Nervous system: Headache

<1%:

Cardiovascular: Acute myocardial infarction, arterial thrombosis, cardiac arrhythmia, chest pain, edema, hypertension, hypotension, increased cardiac enzymes in blood specimen, phlebitis, pulmonary embolism, syncope

Dermatologic: Alopecia, dermatitis, diaphoresis, pallor, skin rash

Endocrine & metabolic: Increased thirst, loss of libido, weight changes

Gastrointestinal: Change in appetite, dysgeusia, dysphagia, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal infection, gastrointestinal inflammation, gingivitis, increased amylase, rectal disease

Genitourinary: Dysuria, glycosuria, gynecological disease (dysmenorrhea, heavy menstrual bleeding, menstrual disease, spotty menstruation, uterine cramps), hematuria, impotence, mastalgia, urinary tract infection

Hematologic & oncologic: Abnormal white blood cell differential, anemia, increased erythrocyte sedimentation rate, purpuric disease, thrombocytopenia

Hepatic: Abnormal hepatobiliary function, increased serum alkaline phosphatase

Hypersensitivity: Anaphylaxis

Nervous system: Anxiety, asthenia, body pain, cerebrovascular accident, chills, confusion, depression, dizziness, drowsiness, fatigue, neuropathy, neurosis, pain, rigors

Neuromuscular & skeletal: Arthralgia, back pain, gout, muscle cramps, myalgia, stiffness

Ophthalmic: Conjunctivitis, visual disturbance

Otic: Deafness, otalgia, tinnitus

Renal: Increased blood urea nitrogen, polyuria

Respiratory: Bronchitis, bronchospasm, dyspnea, epistaxis, pneumonia, upper respiratory tract infection

Miscellaneous: Fever

Frequency not defined: Genitourinary: Abortion, premature labor

Postmarketing:

Genitourinary: Uterine rupture

Hematologic & oncologic: Abnormal platelet aggregation (Beales 1997), prolonged bleeding time (Beales 1997)

Contraindications

Hypersensitivity to misoprostol, other prostaglandins, or any component of the formulation; pregnancy

When used for termination of intrauterine pregnancy (additional contraindications): Refer to Mifepristone monograph.

Warnings/Precautions

Concerns related to adverse effects:

• Abortifacient: Patients must be advised of the abortifacient property and warned not to give misoprostol to others.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular disease.

Other warnings/precautions:

• Appropriate use: Termination of pregnancy: Misoprostol is approved for use with mifepristone for termination of pregnancy. Refer to mifepristone warnings, precautions, and contraindications for appropriate use of misoprostol for this indication.

• Appropriate use: Gastric ulcers: For use only in patients at high risk of complications from gastric ulcers (eg, elderly patients, patients with concomitant diseases) or patients at high risk for developing gastric ulcers (eg, those with a history of ulcers) taking nonsteroidal anti-inflammatory drug (NSAIDs) (including aspirin). Misoprostol must be taken during the duration of NSAID therapy. It is not effective in preventing duodenal ulcers in patients taking NSAIDs.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Cytotec: 100 mcg

Cytotec: 200 mcg [scored]

Generic: 100 mcg, 200 mcg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Cytotec Oral)

100 mcg (per each): $4.79

200 mcg (per each): $6.98

Tablets (miSOPROStol Oral)

100 mcg (per each): $0.50 - $0.98

200 mcg (per each): $0.76 - $1.43

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 100 mcg, 200 mcg

Administration: Adult

Oral:

Nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers, prevention: Administer with food and avoid magnesium-containing antacids (minimizes diarrhea); last dose of the day should be taken at bedtime. Continue therapy through the duration of NSAID therapy. Initiate on the second or third day of a normal menstrual period in patients of reproductive potential.

Termination of intrauterine pregnancy, combination therapy: Refer to the Mifepristone monograph.

Cervical ripening and labor induction (off-label uses): Because the recommended doses require breaking of the commercially available tablets, some reports recommend weighing the tablet fragments (for oral or vaginal use) or preparing a solution (for oral use) to ensure accurate dosing (Ref). An oral solution can be made by dissolving 1 misoprostol 100 mcg tablet in 20 mL warm water, providing a concentration of 5 mcg/mL. Use within 24 hours (Ref).

Misoprostol is available as an oral tablet. Administration of the tablet via the buccal, sublingual, vaginal, and rectal routes has been evaluated. Each route provides different pharmacokinetic and adverse event profiles which may benefit specific indications (Ref).

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 3]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention: To reduce the risk of nonsteroidal anti-inflammatory drug–induced gastric ulcers in patients at high risk of complications.

Termination of intrauterine pregnancy: Medical termination of intrauterine pregnancy through 70 days' gestation in combination with mifepristone (Mifeprex prescribing information).

Use: Off-Label: Adult

Cervical ripening and labor induction; Early pregnancy loss; Incomplete abortion; Postpartum hemorrhage (prevention/treatment); Termination of intrauterine pregnancy (monotherapy)

Medication Safety Issues
Sound-alike/look-alike issues:

Cytotec may be confused with Cytoxan

MiSOPROStol may be confused with metoprolol, miFEPRIStone

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Antacids: May enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea. Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration). Risk X: Avoid combination

Carbetocin: MiSOPROStol may enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced. Risk X: Avoid combination

Oxytocin: MiSOPROStol may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin. Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation. Risk D: Consider therapy modification

Phenylbutazone: May enhance the neurotoxic effect of MiSOPROStol. Specifically, the combination may result in headache, dizziness, and transient diplopia. Risk C: Monitor therapy

Food Interactions

Misoprostol peak serum concentrations may be decreased if taken with food (not clinically significant).

Reproductive Considerations

Misoprostol should not be used for reducing the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in patients of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAIDs, or is at high risk of developing gastric ulceration. When needed, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other patients of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period. Patients must be advised of the abortifacient property and warned not to give the drug to others.

Pregnancy Considerations

Placental transfer of misoprostol acid (the active metabolite of misoprostol) was detected following a single 25 mcg vaginal misoprostol dose for labor induction (de Oliveira Filgueira 2021).

Misoprostol should not be taken by pregnant patients to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drug; the use of misoprostol for this indication is contraindicated during pregnancy.

Misoprostol administration to pregnant patients may cause birth defects, abortion, or premature birth. Congenital anomalies following first trimester exposure include skull defects, cranial nerve palsies, facial malformations, and limb defects. Misoprostol may produce uterine contractions leading to fetal death, uterine perforation, or abortion. Patients must be advised of the abortifacient property. Uterine tachysystole may occur and progress to uterine tetany; uteroplacental blood flow may be impaired and uterine rupture or amniotic fluid embolism leading to adverse fetal heart changes may occur.

Uterine rupture has been reported when misoprostol was administered in pregnant patients to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational age, grand multiparity, and with prior uterine surgery, including cesarean delivery. Uterine activity and fetal status should be monitored in a hospital setting. Misoprostol should not be used in situations where uterotonic drugs are otherwise contraindicated or inappropriate.

Misoprostol is FDA approved for the medical termination of pregnancy of ≤70 days in conjunction with mifepristone (refer to the Mifepristone monograph for details). It is also may be used as monotherapy when mifepristone is not available (ACOG 2020; FIGO [Morris 2017]; WHO 2022). Medical termination of pregnancy is not recommended for patients with chronic adrenal failure, porphyrias, coagulopathy or concurrent anticoagulant therapy, intrauterine device in place, ectopic pregnancy or concurrent long-term corticosteroid therapy (ACOG 2020).

Because misoprostol may induce or augment uterine contractions, it has been used off label as a cervical-ripening agent for induction of labor. Misoprostol should not be used for this purpose during the third trimester in conditions where a spontaneous labor and vaginal delivery would be contraindicated, including patients who have had a prior cesarean delivery or major uterine surgery (because the risk of uterine rupture is increased) (ACOG 2009; ACOG 205 2019).

Misoprostol may be used off-label for the treatment of incomplete abortion (defined as the passage of some but not all products of conception in a patient with an open cervix) (WHO 2022). A systematic review suggests additional data may be needed to determine the most effective misoprostol dose and route of administration (Kim 2017). Misoprostol is also used off-label for the treatment of early pregnancy loss (<13 weeks of gestation), defined as a nonviable, intrauterine pregnancy with either an empty gestational sac or a gestational sac containing an embryo or fetus without fetal heart activity. Use may be considered in patients who do not want to undergo surgical evacuation and who do not show signs of an infection, hemorrhage, severe anemia, or bleeding disorders (ACOG 2018).

Misoprostol is effective for the management of postpartum hemorrhage. Misoprostol as adjunctive therapy with oxytocin has been used off label in high-risk patients; monotherapy is recommended in situations where oxytocin is not available (eg, resource-poor settings). The risk of adverse reactions may be associated with combination therapy (ACOG 2017; FIGO [Escobar 2022]; Gallos 2018; Koch 2019; Morfaw 2019; SOGC [Robinson 2022], Sweed 2018). Various routes of administration have been used for postpartum hemorrhage (buccal, oral, rectal, sublingual, vaginal). Sublingual administration has the highest bioavailability, rapid onset, and a moderate duration of action. Rectal administration has the lowest bioavailability and serum concentrations may not reach clinical significance (SOGC [Robinson 2022]). The oral route produces the most pronounced initial increase in tonus, and rectal and vaginal routes exhibit longer durations of action as compared to oral and sublingual routes (SOGC [Leduc 2018]). Dose-related fever, shivering, nausea, vomiting, and diarrhea are associated with use of misoprostol (FIGO [Escobar 2022]; SOGC [Robinson 2022]). Buccal administration may be associated with lower plasma concentrations and a decreased risk of adverse reactions compared to sublingual administration (Schaff 2005).

Breastfeeding Considerations

Misoprostol acid (the active metabolite of misoprostol) is present in breast milk.

Peak milk concentrations of misoprostol acid occur within 1 hour after an oral maternal dose and generally decline over 5 hours (Abdel-Aleem 2003; Vogel 2004). The authors of one study suggest taking the maternal dose immediately after a feed; the next feed would be acceptable in 3 to 4 hours (Vogel 2004).

The manufacturer recommends that caution be used if administered to patients who are breastfeeding.

Dietary Considerations

When used for the prevention of NSAID-induced ulcers, take with food.

Monitoring Parameters

Cervical ripening and labor induction: Fetal heart rate and uterine activity for 4 hours after each vaginal dose and 2 hours after each oral dose (AWHONN [Simpson 2020]).

Early pregnancy loss: Evaluate Rh status; ultrasound or serial serum β-hCG (if ultrasound not available) 1 to 2 weeks after dosing; patient reported symptoms (ACOG 2018).

Postpartum hemorrhage: heart rate, BP, blood loss, temperature (FIGO [Escobar 2022]).

Prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcers: Pregnancy test within 2 weeks prior to therapy in patients who may become pregnant; adequate diagnostic measures in all cases of undiagnosed abnormal vaginal bleeding.

Termination of intrauterine pregnancy: Refer to Mifepristone monograph.

Mechanism of Action

Misoprostol is a synthetic prostaglandin E1 analog that replaces the protective prostaglandins consumed with prostaglandin-inhibiting therapies (eg, NSAIDs); has been shown to induce uterine contractions

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Inhibition of gastric acid secretion: 30 minutes

Duration of action: Inhibition of gastric acid secretion: 3 hours

Absorption: Rapid and extensive; extensive; food decreases absorption of misoprostol acid

Protein binding: Misoprostol acid: <90%

Metabolism: Hepatic; rapid de-esterification to misoprostol acid (active)

Half-life elimination: Misoprostol acid: 20 to 40 minutes

Time to peak, serum: Misoprostol acid: Fasting: 12 ± 3 minutes

Excretion: Urine (80%)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Cmax, AUC, and t½ are almost doubled, but no clear correlation between degree of impairment and AUC is shown.

Older adult: AUC is increased in patients >64 years of age.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apo-misoprostol | Cytotec;
  • (AR) Argentina: Cytotec | Misop | Misoprost beta;
  • (AT) Austria: Angusta | Cyprostol | Topogyne;
  • (AU) Australia: Cytotec | Gymiso;
  • (BD) Bangladesh: Cytomis | Indula | Miptol | Misoclear | Misopa | Misotab;
  • (BE) Belgium: Angusta | Cytotec;
  • (BF) Burkina Faso: Misoclear;
  • (BG) Bulgaria: Angusta | Topogyne;
  • (BR) Brazil: Prostokos;
  • (CH) Switzerland: Angusta | Cytotec | Misoone;
  • (CI) Côte d'Ivoire: Cytotec;
  • (CL) Chile: Misotrol;
  • (CN) China: Cytotec;
  • (CO) Colombia: Cytil | Cytil fast | Cytil V | Cytotec | Industol | Misoprol | Misopros;
  • (CZ) Czech Republic: Angusta | Cytotec | Mispregnol;
  • (DE) Germany: Angusta | Cytotec | Misoone;
  • (DO) Dominican Republic: Cytotec;
  • (EC) Ecuador: Cytotec;
  • (EE) Estonia: Angusta | Cytotec | Topogyne;
  • (EG) Egypt: Misoprost | Misotac;
  • (ES) Spain: Cytotec | Glefos | Misofar | Misoone;
  • (ET) Ethiopia: Ace miso | Misoprost;
  • (FI) Finland: Angusta | Cytotec | Topogyne;
  • (FR) France: Angusta | Cytotec | Gymiso | Misoone | Misoprostol Dci;
  • (GB) United Kingdom: Angusta | Cytotec | Topogyne;
  • (GR) Greece: Cytotec;
  • (HK) Hong Kong: Apo-misoprostol | Cytotec;
  • (HU) Hungary: Angusta | Cytotec;
  • (ID) Indonesia: Chromalux | Citrosol | Cytotec | Gastrul | Invitec | Mipros | Noprostol | Protecid;
  • (IE) Ireland: Angusta | Cytotec | Misoone;
  • (IL) Israel: Cytotec;
  • (IN) India: Cervisure | Contrapill duo | Cytolog | Emrid | Emtee | Kontrac | M Prost | Mesopil | Miso gyn | Misogen | Misogest | Misogon | Misolast | Misolog | Misolup | Misoprost | Mizolast | Pregclear | Prestakind | Rpitant | Zitotec;
  • (IT) Italy: Angusta | Cytotec | Misodex | Misoone;
  • (JO) Jordan: Cytotec;
  • (JP) Japan: Cytotec;
  • (KE) Kenya: Cytotec | Isovent | Kontrac | Miso kare | Misoclear | Misoprost;
  • (KR) Korea, Republic of: Alsoben | Cirotec | Cystol | Cytotec | Gastec | Gasteck | Gastotec | Gistol | Misel | Misell | Misodol | Misoplus | Mistoren | Nelson misoprostol | Sintec;
  • (LB) Lebanon: Cytotec | Misofar | Misotac;
  • (LT) Lithuania: Cytotec | Miso kare;
  • (LU) Luxembourg: Cytotec;
  • (LV) Latvia: Angusta | Cytotec | Gymiso;
  • (MA) Morocco: Cytotec;
  • (MX) Mexico: Apostecsol | Cyrux | Cytotec | Misoprostol Serral | Myspess | Taneciprol | Tomispral;
  • (MY) Malaysia: Cytotec;
  • (NG) Nigeria: Bleor misoprostol | Chazmax misoprostol | Cytopros | Cytotec | Misoprost | Mistol | Mysotac | Prolon | Texyto;
  • (NL) Netherlands: Angusta | Cytotec;
  • (NO) Norway: Angusta | Cytotec | Topogyne;
  • (NZ) New Zealand: Cytotec;
  • (PE) Peru: Citoprox | Cytofine | Cytotec | Misoprolen | Misoprosmek | Mystol | Prostokos | Tolprax;
  • (PK) Pakistan: Breeky | Cytolog | Cytotol | Liskotol | Mesopil | Miso | Misoclear | Misort | Misotal | Misotin | Mite | S T Mom | Tecmiso | U mol | Zivus;
  • (PL) Poland: Angusta | Cytotec;
  • (PR) Puerto Rico: Cytotec;
  • (PT) Portugal: Cytotec | Misofar;
  • (PY) Paraguay: Ovupros;
  • (QA) Qatar: Cytotec;
  • (RO) Romania: Topogyne;
  • (RU) Russian Federation: Cytotec | Mirolut | Topogin;
  • (SA) Saudi Arabia: Cytotec;
  • (SE) Sweden: Angusta | Cytotec | Topogyne;
  • (SG) Singapore: Cytotec;
  • (SI) Slovenia: Angusta | Topogyne;
  • (SK) Slovakia: Angusta | Cytotec | Mispregnol;
  • (SL) Sierra Leone: Misomife;
  • (TH) Thailand: Cytotec | Misoprostol stada;
  • (TN) Tunisia: Cytotec;
  • (TR) Turkey: Cytotec;
  • (TW) Taiwan: Cytotec | U-miso;
  • (UA) Ukraine: Gastrotec | Mirolut | Misostol | Misotab;
  • (UG) Uganda: Cytotec | Kontrac | Miso kare | Misoclear | Misofree | Misopro | Misoprost;
  • (UY) Uruguay: Cytotec | Partum;
  • (VE) Venezuela, Bolivarian Republic of: Cytotec;
  • (VN) Viet Nam: Heraprostol;
  • (ZA) South Africa: Ace miso | Cytotec;
  • (ZM) Zambia: Cytotec | Kontrac | L pill | Misoclear | Misoprost | Misotac;
  • (ZW) Zimbabwe: Celprotec | Cytotec | Misoclear | Misoprost
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). United States Pharmacopeia Convention; 2020:74-92.
  2. Abdel-Aleem H, Villar J, Gülmezoglu AM, et al. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol. 2003;108(1):25-28. [PubMed 12694965]
  3. Abubeker FA, Lavelanet A, Rodriguez MI, Kim C. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. BMC Womens Health. 2020;20(1):142. doi:10.1186/s12905-020-01003-8 [PubMed 32635921]
  4. Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2014;(6):CD001338. doi:10.1002/14651858.CD001338.pub3 [PubMed 24924489]
  5. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 200: early pregnancy loss. Obstet Gynecol. 2018;132(5):e197-e207. doi: 10.1097/AOG.0000000000002899. [PubMed 30157093]
  6. American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum hemorrhage. Obstet Gynecol. 2017;130(4):e168-e186. doi:10.1097/AOG.0000000000002351. [PubMed 28937571]
  7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 107: Induction of Labor. Obstet Gynecol. 2009;114(2, pt 1):386-397. doi:10.1097/AOG.0b013e3181b48ef5 [PubMed 19623003]
  8. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 205: Vaginal birth after cesarean delivery. Obstet Gynecol. 2019;133(2):e110-e127. doi: 10.1097/AOG.0000000000003078. [PubMed 30681543]
  9. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, Society of Family Planning. Medication abortion up to 70 days of gestation: ACOG Practice Bulletin, Number 225. Obstet Gynecol. 2020;136(4):e31-e47. doi:10.1097/AOG.0000000000004082 [PubMed 32804884]
  10. Amini M, Wide-Swensson D, Herbst A. Sublingual misoprostol vs. oral misoprostol solution for induction of labor: a retrospective study. Front Surg. 2022;9:968372. doi:10.3389/fsurg.2022.968372 [PubMed 36189381]
  11. Beales IL, Clemons M, Kong WM. Misoprostol-associated platelet aggregation dysfunction and increased gastrointestinal blood loss. Eur J Gastroenterol Hepatol. 1997;9(1):91-92. doi:10.1097/00042737-199701000-00021 [PubMed 9031907]
  12. Berghella V, Bellussi F, Schoen CN. Evidence-based labor management: induction of labor (part 2). Am J Obstet Gynecol MFM. 2020;2(3):100136. doi:10.1016/j.ajogmf.2020.100136 [PubMed 33345875]
  13. Bhullar A, Carlan SJ, Hamm J, Lamberty N, White L, Richichi K. Buccal misoprostol to decrease blood loss after vaginal delivery: a randomized trial. Obstet Gynecol. 2004;104(6):1282‐1288. doi:10.1097/01.AOG.0000144119.94565.18 [PubMed 15572491]
  14. Bohlmann MK, Rath W. Medical prevention and treatment of postpartum hemorrhage: a comparison of different guidelines. Arch Gynecol Obstet. 2014;289(3):555-567. doi: 10.1007/s00404-013-3016-4. [PubMed 24006033]
  15. Chen W, Xue J, Peprah MK, et al. A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour. BJOG. 2016;123(3):346-354. doi:10.1111/1471-0528 [PubMed 26538408]
  16. Chu JJ, Devall AJ, Beeson LE, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10253):770-778. doi:10.1016/S0140-6736(20)31788-8 [PubMed 32853559]
  17. Cleghorn GJ, Shepherd RW, Holt TL. The Use of a Synthetic Prostaglandin E1 Analogue (Misoprostol) as an Adjunct to Pancreatic Enzyme Replacement in Cystic Fibrosis. Scand J Gastroenterol Suppl. 1988;143:142-147. [PubMed 3133753]
  18. Cytotec (misoprostol) [prescribing information]. New York, NY: Pfizer; February 2021.
  19. de Oliveira Filgueira GC, de Fátima Pinto Rodrigues G, Benzi JRL, et al. Determination of misoprostol acid in plasma samples by UPLC-MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor. J Pharm Biomed Anal. 2021;202:114138. doi:10.1016/j.jpba.2021.114138 [PubMed 34022668]
  20. Dorr ML, Pierson RC, Daggy J, Quinney SK, Haas DM. Buccal versus vaginal misoprostol for term induction of labor: a retrospective cohort study. Am J Perinatol. 2019;36(7):765-772. doi:10.1055/s-0038-1675219 [PubMed 30380580]
  21. Escobar MF, Nassar AH, Theron G, et al; FIGO Safe Motherhood and Newborn Health Committee. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet. 2022;157(suppl 1):3-50. doi:10.1002/ijgo.14116 [PubMed 35297039]
  22. FIGO Working Group on Prevention of Unsafe Abortion and its Consequences; International Federation of Gynecology and Obstetrics. The combination of mifepristone and misoprostol for the termination of pregnancy [published correction appears in Int J Gynaecol Obstet. 2011;115(3):332]. Int J Gynaecol Obstet. 2011;115(1):1-4. [PubMed 21872858]
  23. Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2018;12(12):CD011689. doi:10.1002/14651858.CD011689.pub3 [PubMed 30569545]
  24. Gomez HB, Hoffman MK, Caplan R, Ruhstaller K, Young MHH, Sciscione AC. Buccal vs vaginal misoprostol combined with Foley catheter for cervical ripening at term (the BEGIN trial): a randomized controlled trial. Am J Obstet Gynecol. 2021;224(5):524.e1-524.e8. doi:10.1016/j.ajog.2021.02.016 [PubMed 33617796]
  25. Haas DM, Daggy J, Flannery KM, et al. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol. 2019;221(3):259.e1-259.e16. doi:10.1016/j.ajog.2019.04.037 [PubMed 31075246]
  26. Hamm J, Russell Z, Botha T, Carlan SJ, Richichi K. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005;192(5):1404‐1406. doi:10.1016/j.ajog.2004.12.033 [PubMed 15902121]
  27. Hernández-Castro F, López-Serna N, Treviño-Salinas EM, Soria-López JA, Sordia-Hernández LH, Cárdenas-Estrada E. Randomized double-blind placebo-controlled trial of buccal misoprostol to reduce the need for additional uterotonic drugs during cesarean delivery. Int J Gynaecol Obstet. 2016;132(2):184‐187. doi:10.1016/j.ijgo.2015.06.060 [PubMed 26534874]
  28. Kerr RS, Kumar N, Williams MJ, et al. Low-dose oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2021;6(6):CD014484. doi:10.1002/14651858.CD014484 [PubMed 34155622]
  29. Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017;1(1):CD007223. doi:10.1002/14651858.CD007223.pub4 [PubMed 28138973]
  30. Koch DM, Rattmann YD. Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach. Einstein (Sao Paulo). 2019;18:eAO5029. doi:10.31744/einstein_journal/2020AO5029 [PubMed 31721897]
  31. Kumar N, Haas DM, Weeks AD. Misoprostol for labour induction. Best Pract Res Clin Obstet Gynaecol. 2021;77:53-63. doi:10.1016/j.bpobgyn.2021.09.003 [PubMed 34607746]
  32. Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol for induction of labor: a systematic review. Obstet Gynecol. 2009;113(2, pt 1):374-383. doi:10.1097/AOG.0b013e3181945859 [PubMed 19155909]
  33. Leduc D, Senikas V, Lalonde AB. No. 235-active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2018;40(12):e841‐e855. doi:10.1016/j.jogc.2018.09.024 [PubMed 30527079]
  34. Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories; October 2020.
  35. Morfaw F, Fundoh M, Pisoh C, et al. Misoprostol as an adjunct to oxytocin can reduce postpartum-haemorrhage: a propensity score-matched retrospective chart review in Bamenda-Cameroon, 2015-2016. BMC Pregnancy Childbirth. 2019;19(1):257. doi:10.1186/s12884-019-2407-3 [PubMed 31331275]
  36. Morris JL, Winikoff B, Dabash R, et al. FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynaecol Obstet. 2017;138(3):363‐366. doi:10.1002/ijgo.12181 [PubMed 28643396]
  37. Muñoz M, Stensballe J, Ducloy-Bouthors AS, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus. 2019;17(2):112-136. doi:10.2450/2019.0245-18 [PubMed 30865585]
  38. Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2004;2004(4):CD004221. doi:10.1002/14651858.CD004221.pub2 [PubMed 15495088]
  39. Pergialiotis V, Panagiotopoulos M, Constantinou T, et al. Efficacy and safety of oral and sublingual versus vaginal misoprostol for induction of labour: a systematic review and meta-analysis. Arch Gynecol Obstet. 2023;308(3):727-775. doi:10.1007/s00404-022-06867-9 [PubMed 36472645]
  40. Rahimi M, Haghighi L, Baradaran HR, et al. Comparison of the effect of oral and vaginal misoprostol on labor induction: updating a systematic review and meta-analysis of interventional studies. Eur J Med Res. 2023;28(1):51. doi:10.1186/s40001-023-01007-8 [PubMed 36707858]
  41. Robinson D, Basso M, Chan C, Duckitt K, Lett R. Guideline no. 431: postpartum hemorrhage and hemorrhagic shock. J Obstet Gynaecol Can. 2022;44(12):1293-1310.e1. doi:10.1016/j.jogc.2022.10.002 [PubMed 36567097]
  42. Robinson D, Campbell K, Hobson SR, MacDonald WK, Sawchuck D, Wagner B. Guideline no. 432c: induction of labour. J Obstet Gynaecol Can. 2023;45(1):70-77.e3. doi:10.1016/j.jogc.2022.11.009 [PubMed 36725134]
  43. Robinson PJ, Smith AL, Sly PD. Duodenal pH in Cystic Fibrosis and Its Relationship to Fat Malabsorption. Dig Dis Sci. 1990;35(10):1299-1304. [PubMed 2120019]
  44. Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception. 2005;71(1):22‐25. doi:10.1016/j.contraception.2004.06.014 [PubMed 15639067]
  45. Schreiber CA, Creinin MD, Atrio J, et al. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med. 2018;378(23):2161-2170. doi: 10.1056/NEJMoa1715726. [PubMed 29874535]
  46. Simpson KR. Cervical ripening and labor induction and augmentation, 5th edition. Nurs Womens Health. 2020;24(4):S1-S41. doi:10.1016/j.nwh.2020.04.005 [PubMed 32778395]
  47. Sweed MS, El-Saied MM, Abou-Gamrah AE, et al. Rectal vs. sublingual misoprostol before cesarean section: double-blind, three-arm, randomized clinical trial. Arch Gynecol Obstet. 2018;298(6):1115‐1122. doi:10.1007/s00404-018-4894-2 [PubMed 30291483]
  48. Tang J, Kapp N, Dragoman M, et al. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet. 2013;121(2):186-189. doi: 10.1016/j.ijgo.2012.12.009. [PubMed 23433680]
  49. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(suppl 2):S160-S167. doi:10.1016/j.ijgo.2007.09.004 [PubMed 17963768]
  50. Ugwu IA, Oluwasola TA, Enabor OO, et al. Randomized controlled trial comparing 200μg and 400μg sublingual misoprostol for prevention of primary postpartum hemorrhage. Int J Gynaecol Obstet. 2016;133(2):173-177. doi: 10.1016/j.ijgo.2015.09.026. [PubMed 26892695]
  51. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed October 5, 2016.
  52. Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol. 2004;191(6):2168-2173. [PubMed 15592308]
  53. Walt RP. Misoprostol for the Treatment of Peptic Ulcer and Anti-inflammatory Drug-Induced Gastroduodenal Ulceration. N Engl J Med. 1992;327(22):1575-1580. [PubMed 1435885]
  54. Weeks AD, Lightly K, Mol BW, Frohlich J, Pontefract S, Williams MJ; Royal College of Obstetricians and Gynaecologists. Evaluating misoprostol and mechanical methods for induction of labour: scientific impact paper no. 68 April 2022. BJOG. 2022;129(8):e61-e65. doi:10.1111/1471-0528.17136 [PubMed 35478481]
  55. Whitehouse K, Brant A, Fonhus MS, Lavelanet A, Ganatra B. Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis. Contracept X. 2020;2:100037. doi:10.1016/j.conx.2020.100037 [PubMed 32954250]
  56. Williams MC, Tsibris JC, Davis G, Baiano J, O'Brien WF. Dose variation that is associated with approximated one-quarter tablet doses of misoprostol. Am J Obstet Gynecol. 2002;187(3):615-619. doi:10.1067/mob.2002.124959 [PubMed 12237637]
  57. Wing DA. Labor Induction With Misoprostol. Am J Obstet Gynecol. 1999;181(2):339-345. [PubMed 10454679]
  58. World Health Organization (WHO). Abortion Care Guideline. World Health Organization; 2022. https://www.ncbi.nlm.nih.gov/books/NBK578942/.
  59. World Health Organization (WHO) recommendations. Uterotonics for the prevention of postpartum haemorrhage. Published 2018. https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1. Accessed January 23, 2023.
  60. World Health Organization (WHO). WHO recommendations for induction of labour. Published September 6, 2011. https://www.who.int/publications/i/item/9789241501156. Accessed August 29, 2023.
  61. Yenuberi H, Mathews J, George A, et al. The efficacy and safety of 25 μg or 50 μg oral misoprostol versus 25 μg vaginal misoprostol given at 4- or 6-hourly intervals for induction of labour in women at or beyond term with live singleton pregnancies: a systematic review and meta-analysis. Int J Gynaecol Obstet. Published online July 3, 2023. doi:10.1002/ijgo.14970 [PubMed 37401143]
  62. Zhang J, Gilles JM, Barnhart K, et al; National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005;353(8):761-769. doi: 10.1056/NEJMoa044064. [PubMed 16120856]
Topic 9657 Version 316.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟